<DOC>
	<DOC>NCT02112838</DOC>
	<brief_summary>The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy</brief_summary>
	<brief_title>Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>Renal biopsy findings consistent with IgA nephropathy Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated) dose Proteinuria &gt; 1 gm/day at diagnosis of IgA nephropathy and Proteinuria &gt; 0.50 gm/day at the second Screening Visit Blood pressure controlled to â‰¤ 130/80 with angiotensin blockade with or without other antihypertensive agents Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab. Use of &gt; 15 mg/day prednisone (or other corticosteroid equivalent).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IGA Glomerulonephritis</keyword>
	<keyword>Nephritis, IGA Type</keyword>
</DOC>